Angiotensin-(1-7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes. 2012

Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.

The renin-angiotensin system is an important link between metabolic syndrome and cardiovascular diseases. Besides angiotensin II, other angiotensin peptides such as angiotensin-(1-7), have important biological activities. It has been demonstrated that angiotensin-(1-7), acting through the G protein-coupled receptor encoded by the Mas protooncogene have important actions on the cardiovascular system. However, the role of angiotensin-(1-7)-Mas axis in lipidic profile is not well established. In the present study, the adipocyte metabolism was investigated in wild type and FVB/N Mas-deficient male mice. The gene expression of peroxisome proliferator-activated receptor gamma, acetyl-CoA carboxylase and the amount of fatty acid synthase protein were reduced in the Mas-knockout mice. Serum nonesterified fatty acids of Mas-knockout showed a 50% increase in relation to wild type group. Basal and isoproterenol-stimulated lipolysis was similar between the groups, however, a significant decrease of the glycerol release (lipolytic index) in response to insulin was observed in wild type animals, while no effect of the insulin action was observed in a Mas-knockout group. The data suggest that the lack of angiotensin-(1-7) action through Mas receptor alters the response of adipocytes to insulin action. These effects might be related to decreased expression of PPARγ.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007545 Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. Isoprenaline,Isopropylarterenol,4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol,Euspiran,Isadrin,Isadrine,Isopropyl Noradrenaline,Isopropylnoradrenaline,Isopropylnorepinephrine,Isoproterenol Hydrochloride,Isoproterenol Sulfate,Isuprel,Izadrin,Norisodrine,Novodrin,Hydrochloride, Isoproterenol,Noradrenaline, Isopropyl,Sulfate, Isoproterenol
D008066 Lipolysis The metabolic process of breaking down LIPIDS to release FREE FATTY ACIDS, the major oxidative fuel for the body. Lipolysis may involve dietary lipids in the DIGESTIVE TRACT, circulating lipids in the BLOOD, and stored lipids in the ADIPOSE TISSUE or the LIVER. A number of enzymes are involved in such lipid hydrolysis, such as LIPASE and LIPOPROTEIN LIPASE from various tissues. Lipolyses
D008297 Male Males
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D005990 Glycerol A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, or sweetening agent. 1,2,3-Propanetriol,Glycerin,1,2,3-Trihydroxypropane,Glycerine
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D000103 Acetyl-CoA Carboxylase A carboxylating enzyme that catalyzes the conversion of ATP, acetyl-CoA, and HCO3- to ADP, orthophosphate, and malonyl-CoA. It is a biotinyl-protein that also catalyzes transcarboxylation. The plant enzyme also carboxylates propanoyl-CoA and butanoyl-CoA (From Enzyme Nomenclature, 1992) EC 6.4.1.2. Acetyl Coenzyme A Carboxylase,Acetyl CoA Carboxylase,Carboxylase, Acetyl-CoA

Related Publications

Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
May 2004, Circulation,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
January 2003, Endocrinology,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
July 2002, Chest,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
March 2004, The Journal of biological chemistry,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
March 2008, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
April 1999, Diabetes,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
December 2000, Endocrinology,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
June 2020, Oncogenesis,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
March 2001, The Journal of biological chemistry,
Erica Guilhen Mario, and Sérgio Henrique S Santos, and Adaliene Versiane M Ferreira, and Michael Bader, and Robson Augusto S Santos, and Leida Maria Botion
February 2001, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!